Ask AI
ProCE Banner Activity

DYNAMIC-III: De-escalation of Adjuvant CT in the Postoperative ctDNA-Negative Cohort of Patients With Stage III Colon Cancer

Conference Coverage
Slideset

For patients with stage III colon cancer and negative ctDNA findings after resection, ctDNA-guided adjuvant therapy de-escalation was feasible, reduced oxaliplatin exposure with improved safety outcomes and with 3-year recurrence-free survival outcomes comparable to standard of care.

Released: October 31, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly